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Introduction
With the increased prevalence of chronic diseases 
predominantly driven by an increasing ageing population, 
healthcare demand in Ireland has grown. It is predicted 
that 40% of adults in Ireland will have one or more chronic 
conditions by 20201 while internationally chronic 
disease and multi-morbidity is set to increase.2,3 Given the 
challenges of scarce resources and constrained public 
finances, effective dissemination of a health budget is 
challenging. The growing demand in medication use, 
particularly by the elderly as well as the rising costs of 
medicines increases the importance of pharmacist services. 
Compounding this is the recent recommendation in Ireland 
that patients in acute hospital settings should receive 
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pharmacist-led medication reviews in line with Health 
Service Executive (HSE) integrated care guidelines.4
Medication is one of the most common medical 
interventions to prevent, treat and manage disease and 
illness.5 There are numerous studies that have investigated 
the impact of inappropriate prescribing and potential 
adverse drug events (ADEs) which have cost implications 
for healthcare systems.6,7 In many hospitals, dedicated 
clinical pharmacy services are available to provide 
pharmacist interventions (PIs) to optimise medication 
therapy and potentially reduce the occurrence of ADEs. In 
Ireland and elsewhere, variations are reported in the level 
of frequency and availability of clinical pharmacy services, 
predominantly due to a lack of resources.8 This may be 
compounded by the fact that within the Irish jurisdiction 
there are no national standards of practice in place for 
clinical pharmacy.4
A clinical medication review is defined as,
the process where a health professional reviews the patient, 
the illness, and the drug treatment during a consultation. It 
involves evaluating the therapeutic efficacy of each drug and 
the progress of the conditions being treated. Other issues, 
such as compliance, actual and potential adverse effects, 
interactions, and the patient’s understanding of the condition 
and its treatment are considered when appropriate. The 
outcome of the review will be a decision about the continuation 
(or otherwise) of the treatment.9
In this study, a clinical medication review was a review 
of the patients’ prescribed medicines by a pharmacist. A 
medication review by a hospital pharmacist can result in 
PI(s). A previous study found variations in the current 
practice of reviewing medications among hospital 
inpatients, with some patients not receiving any formal 
medication review.8 A systematic literature review has 
shown the benefits of clinical medication review with PIs 
leading to a reduction of; inappropriately prescribed 
medicines; risk of ADEs and hospital stays,8,10–12 but 
previous studies have highlighted the need for a more 
rigorous cost analyses using a more quantitative approach.12 
A budget impact analysis (BIA) is defined as a tool to 
predict the potential financial impact of the adoption and 
diffusion of a new technology into a healthcare system 
with finite resources.13 Therefore, the aim of this study is 
to conduct a BIA to evaluate the net effect of a clinical 
medication review, conducted by a pharmacist. This article 
measures the costs associated with the delivery of a 
pharmacist-led medication review and estimates the 
savings generated from this intervention on a per-patient 
basis.
A BIA is then conducted from a health provider’s 
perspective using projected inpatient discharge rates in all 




An audit was conducted in an acute urban university 
teaching hospital, situated in the south of Ireland and 
serving a population of 417,211 with 350 beds.14 Ethical 
approval was granted by the Clinical Research Ethics 
Committee of the Cork Teaching Hospitals, University 
College Cork. Data were collected over a 6-month time 
period from 01 May 2015 to 01 November 2015. For the 
purposes of this study, patients received a pharmacist-led 
medication review on average twice weekly. In this study, 
a total of 1216 patients received medication reviews over 
this period.
Clinical medication review
In this study the pharmacist-led medication review 
consisted of a patient drug kardex review (a drug kardex is 
equivalent to a hospital inpatient prescription) and, if 
required, was supported by the patient notes and laboratory 
data but did not involve the patient as a source of data. 
When a need for a PI(s) was identified, it was brought to 
the attention of the patient’s medical or surgical team for 
review. PIs identified were classified according to type,15 
and the medicines associated with the PIs were coded 
using the Anatomical Therapeutic Chemical (ATC) 
Classification System.16
A multidisciplinary approach was adopted to determine 
the likelihood of an ADE occurring, using an expert panel 
with the inclusion of a general practitioner (GP) and an 
academic pharmacist, to the panel of hospital pharmacists.15 
This is similar to Gallagher et al.10 who also employed an 
expert panel to determine the likelihood of an ADE 
occurring if the PI had not been implemented. The panel 
members independently assigned a probability score to 
each PI (Table 1). This score reflected the likelihood of an 
ADE occurring if the PI had not taken place. Five categories 
were used to score the likelihood of an ADE occurring10 
(Table 1).
The median probability score for each PI was used in 
the analysis (Table 1). An inter-rater reliability (IRR) 
analysis using Cohen’s Kappa statistic was performed to 
determine agreement among raters.15
Cost of clinical medication review
A micro-costing approach was adopted to identify, 
measure, and value the costs associated with providing a 
clinical medication review. In contrast to previous 
approaches, an observational study recorded the total time 
it took for the pharmacist to deliver the medication reviews 
and resulting PI(s) during the study period, and the average 
on a per-patient basis was then calculated. The hourly cost 
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of employing a hospital pharmacist is calculated using the 
HSE salary scales.17 The hourly cost of employing a 
hospital pharmacist was then used, and pay-related social 
insurance (PRSI), pension contributions and hospital 
overheads were included in the cost, in line with Health 
Information and Quality Authority (HIQA) guidelines.18
Potential savings were then determined based on the 
opportunity cost of avoiding an ADE in direct healthcare 
which could have occurred in the absence of a clinical 
medication review. The associated costs of an ADE have 
been previously found to be €1057 on average per patient.10 
By using the cost of an ADE averted and applying a 
probability that an ADE would have occurred, without the 
medication review, potential savings from ADEs averted 
in the short term were calculated.
Once the costs of the delivery of medication reviews 
and potential savings from ADEs averted were calculated, 
the net benefit of medication reviews was determined 
using a BIA.
A BIA estimates the net benefits from a medication 
review clinical pharmacy service over time. When 
undertaking the BIA, a HSE perspective was taken as 
recommended by HIQA.18 The target population were 
inpatients in an acute hospital in the south of Ireland. The 
age and sex of these inpatients are described in Table 3 in 
Appendix 1. Population and inpatient discharge data from 
the Hospital Inpatient Enquiry (HIPE) database19 and 
projected population rates were calculated using data from 
the census of population.14 These were used to determine 
and project population trends and predict discharge rates 
for the next 5 years. A top-down population approach was 
adopted to estimate the annual number of target inpatients. 
The resulting net benefit from medication reviews was 
then projected over a timeframe of 5 years using population 
estimates.
Results
A total of 1670 pharmacist-led medication reviews were 
delivered to 1216 patients, and PIs were identified in 213 
patients (Figure 1). Patients aged ⩽17 years or those on 
speciality wards such as oncology were not included in the 
study. A total of 60.7% of PIs had a ‘medium’ or ‘high’ 
likelihood of causing an ADE.
The majority of patients with PIs were female which is 
expected given higher utilisation rates of health service by 
female patients (refer to Table 3 in Appendix 1). The 
median age of patients with PIs was 74 years. The majority 
of patients (90%) with PIs were not undergoing a surgical 
procedure. The median length of stay for patients with PIs 
was 10 days. A total of 843 co-morbidities were identified 
in patients with PIs, which generated a median value of 
four co-morbidities per patient. The most common 
condition identified for patients was hypertension (n = 88).
The resulting PIs and their prevalence are displayed in 
Table 4 in Appendix 1. The IRR analysis using Cohen’s 
Kappa statistic determined agreement among raters and 
ranged from slight (0.114) to fair (0.324).15 Duplication of 
drug/drug class, poor prescribing practice, frequency, dose 
and drug–drug interaction were the PIs predominantly 
identified.
It took 180 hours to deliver the medication reviews and 
resulting PI(s) to 1216 inpatients during the 6-month study 
period. From the observational study, the average time it 
took to deliver a medication review and resulting PI(s) was 
estimated at 6 minutes 28 seconds per patient. The cost of a 
pharmacist-led medication review and resulting PI(s) per 
patient in an acute public hospital was calculated as €4.70. 
Therefore, the cost of a bi-weekly medication review and 
Table 1. PIs and assigned probabilities.
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ADE: adverse drug event.
Figure 1. Medication review intervention flow diagram.
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resulting PI(s) was €9.40 per patient and used as the 
baseline.
Potential savings from ADEs averted were estimated by 
using the probability of an ADE which could have occurred 
in the absence of a clinical medication review. Gallagher 
et al. estimated that an ADE costs €1057 on average. There 
were 313 PIs identified in 213 patients. These 213 patients 
were from a sample size of 1216 patients. Therefore, the 
probability of a PI for the sample was estimated at 0.175. 
Duplication of drug/drug class, poor prescribing practice, 
frequency, dose and drug–drug interaction were found to 
be responsible for >70% of the PIs identified (Table 4 in 
the Appendix 1). Almost two-thirds (61%) of the total 
number of PIs were categorised by the expert panel as 
having a ‘medium’ to ‘high’ likelihood of an ADE 
occurring while the remaining 39% had a ‘low’ to ‘zero’ 
classification (Table 1). Taking into consideration the 
categorisation of patients (Table 1), the probability of an 
ADE occurring for those patients who required a PI is 
0.293. The probability of an ADE (probability of an ADE 
for those who required a PI multiplied by the probability of 
a PI for the sample) for the total population is 0.051.
Assuming the cost of an ADE is €1084 (adjusted for 
inflation to 2017 prices) per patient, and given the 
probability of an ADE for the total population (0.051), the 
expected monetary benefit of an ADE avoided is €55.28 
per patient (only taking into consideration the direct 
healthcare costs). Once the cost of the intervention is 
deducted (assuming all patients received a medication 
review bi-weekly is €9.40) the net benefit is €45.88 per 
patient.
To estimate the projected cost of service delivery, the 
cost of service delivery per patient was used as a baseline 
calculated at €9.40 per patient (bi-weekly medication 
review), then extrapolated and calculated over a 5-year 
period for inpatient discharge data. The projected number 
of inpatient discharges was estimated using the HIPE 
system (Table 2).19 The estimated annual cost of delivery 
for the 2017–2021 period is projected to be between €6–
€6.4 m for all acute public hospitals in Ireland.
To estimate the projected annual net benefit, the average 
saving from an ADE averted minus the cost of the 
intervention applied to the expected population is 
calculated. The expected monetary benefit of an ADE 
avoided is €55.28 per patient, and this is used as the 
baseline. The projected expected annual monetary benefit 
from an ADE avoided when direct healthcare costs are 
considered varies between €35.5–€37.6 m for the period 
2017–2021 (Table 2). Whereas, the projected annual net 
benefit varies between €29.5–€31.2 m from 2017–2021.
Sensitivity analyses
To take into account uncertainty in the model, sensitivity 
analyses were applied. The length of stay in a public hospital, 
salary scales, the likelihood of an ADE, the time taken to 
complete a clinical medication review and the associated 
costs of an ADE were examined. Within the literature, it is 
recommended to complete a medication review of patients 
every day.8 However, due to a lack of resources, a 
medication review of each patient could only be 
implemented in this study at most twice per week. If 
consideration was given to a daily medication review, this 
would have implications on the cost of delivery. Previous 
literature has found that patients with ADE stay marginally 
longer than the average stay, between 6.52–7.27 days with 
an average of 6.64 days.20,21 The direct annual cost of daily 
medication reviews for all patients in acute hospitals 
would be €20–€21.2 m in years 2017–2021(assuming 
6.64 days; refer to Table 5 in Appendix 1). The resulting 
net benefit would be €98–€103 m in years 2017–2021. 
When variation in hospital stay is considered, the resulting 
net benefit changes but still remains positive between 
€96–€113 m.
For the purposes of this study, the midpoint on the 
pharmacist salary scale was used to calculate the cost of 
service delivery. However, if this was allowed to vary to 
reflect the lowest point on the scale and the highest point 
on the scale of a higher grade (senior pharmacist salary 
scale), cost would vary between €3.24 and €6.72 per 
Table 2. Projected cost and savings from ADEs averted.
2017 2018 2019 2020 2021
Estimated Populationa 4,796,537 4,859,137 4,922,555 4,986,800 5,051,884
Total inpatient dischargesb 643,008 651,932 660,980 670,153 679,454
Total cost of medication 
reviews
€6,044,275 €6,128,161 €6,213,212 €6,299,443 €6,386,871
Expected monetary benefit 
from ADE avoided
€35,545,478 €36,038,802 €36,538,972 €37,046,084 €37,560,235
Projected net benefit €29,501,204 €29,910,641 €30,325,761 €30,746,642 €31,173,364
ADE: adverse drug event.
Projections do not take into account changes in activity due to models of care, disease patterns, medical inflation, changes in policy on eligibility, the 
health of the population, the expectations of the public or the state of the national economy.
aProjected population estimates Census 2016 M1F1 scenario (CSO, 2016).
bProjected inpatient discharges HIPE (2015).
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patient (assuming bi-weekly medication reviews). Then 
the projected annual costs for bi-weekly medication 
reviews would increase or decrease depending on salary 
scale by approximately €2 m on average across the same 
time period (refer to Table 6 in Appendix 1). With the 
resulting net benefit on average €32.2 m for the lowest 
point on the scale (pharmacist salary scale) and €27.7 m 
for the highest point on the scale (senior pharmacist salary 
scale) across the same time period. This also resulted in a 
positive cost benefit ratio (see Figure 2 in Appendix 1).
The likelihood of an ADE avoided was varied each 
way by 50%,10 and the expected benefit varies between 
€27.64 and €82.93 per patient. When costs per patient 
were considered, the expected net benefit was still 
positive, ranging between approximately €18 and €74 per 
patient (assuming delivery of bi-weekly medication reviews) 
with cost benefit ratios positive also (see Figure 2 in 
Appendix 1).
The time taken to complete the intervention was on 
average 6 minutes 28 seconds per patient. This reflects the 
time taken to deliver a drug kardex review and resulting 
PI(s) per patient. Previous literature in this area presents a 
wide variation in time taken to complete clinical pharmacy 
services. This suggests that the design of the study (i.e. 
what is included in the intervention) strongly influences 
the time taken to deliver the intervention. Therefore, it 
proved difficult to make comparisons across studies. For 
example, in some studies, a medication reconciliation was 
included in the intervention, while in others this was not 
the case.10 Given previous literature, a range of between 5 
and 30 minutes per patient was used.21–24 The expected 
cost varies between €7.49 and €44.93 per patient. The 
resulting net benefit is positive and varied between €10.35 
and €47.79 per patient, with the overall cost benefit ratio 
remaining positive (see Figure 2 in Appendix 1).
This was a retrospective study, so a micro-costing of the 
associated costs of ADE was not possible. Replicating 
costs were the only data available to this study, as estimated 
costs of an ADE for hospital inpatients from the Irish 
Healthcare system were not available. Therefore, it was 
agreed that the estimated costs of an ADE for hospital 
inpatients was €1084 per patient, as it was the only cost 
cited in any Irish research.10 It is a cost from another 
healthcare jurisdiction that has been converted to reflect 
cost of living differences. It is questionable as to whether 
it is in fact reflective of the Irish healthcare system. To 
demonstrate variation in cost, previously published ADE 
outcome measures ranging from €934–€5783 per case10 
were used. The diagnosis-related group (DRG) estimates 
measure exclusively allergic reactions to drugs and are 
generally less accurate than micro-costing studies, but 
these are captured in the range. In addition, more recent 
international studies were also examined but reported 
mean costs within the range €934–€5783 per case.20,21 
Poudel et al.20 highlighted that higher costs reported in 
earlier studies may be due to a lack of adjustment for 
length of stay or operative procedures. Therefore, this 
range seems to be the most appropriate. When associated 
costs of ADE vary, the expected benefit varies between 
€47.63 and €294.93 per patient. When costs per patient are 
considered, the expected net benefit would still be positive 
ranging between approximately €38.23 and €284.93 per 
patient (assuming delivery of bi-weekly medication 
reviews). This phenomenon results in positive cost benefit 
ratios (refer Figure 2 in Appendix 1).
Limitations
The study design and setting influenced the number of PIs 
identified. In this study, the pharmacist-led medication 
review consisted of a patient drug kardex review. A PI rate 
(number of PI(s) per patient who received a PI(s)) of 1.47 
was reported in this study, which was lower than the rate 
of 1.98 reported in a similar study conducted in a university 
teaching hospital in Ireland.10 However, in Gallagher 
et al, medicine omissions, relative to admission notes, 
represented 43% of the PIs in comparison to 4% of the PIs 
in this study. Medication reconciliation, identifying 
medication omissions relative to admission notes, was 
only opportunistically performed in this study.
In addition, in contrast to Gallagher et al., a multi-
disciplinary approach was adopted in this study to 
determine the likelihood of an ADE, with the addition of 
a GP and an academic pharmacist to the panel of hospital 
pharmacists as recommended by previous research.10,15 
The composition of the panel and the classi-fication of 
PIs may have contributed to the probability of an ADE. 
Furthermore, two of the five most prevalent high-alert 
medicines as identified by the Institute for Safe 
Medication Practices (United States) were included, 
which would affect the probability of an ADE, while 
none of these medicines were included in the Gallagher 
et al. paper.10,25
The associated costs of an ADE were found to be €1084 
on average per patient10 and was used in this study. 
However, it is important to acknowledge that taking an 
average cost across ADEs although beneficial can 
underestimate potential cost savings that could be made 
with certain illnesses. This can have an impact on cost 
savings. This was a retrospective study so the opportunity 
to collect patient records was not possible in order to 
complete a micro-costing of patient outcomes. In addition, 
there is a lack of published data costing an ADE in the Irish 
Healthcare system. The ADE cost from the Gallagher et al 
paper was used, and a sensitivity analysis around the ADE 
was presented.
Collecting information on patients who did not undergo 
a medication review was not possible, as this was a 
retrospective study. Therefore, this study could not 
determine whether there was a statistically significant 
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difference between patients who had the intervention 
versus those that did not. This was a single-site study, and 
expanding the number of sites would have produced more 
data which would have increased the generalisability of 
the findings.
Gallagher et al (using results from a previous published 
study) reports a time of 15–30 minutes per PI. The study 
design has been found to influence the time taken to deliver 
the intervention. In this study, the intervention consisted of 
a patient drug kardex review, whereas in Gallagher et al., 
the definition of the intervention was much broader and 
included medicines reconciliation which can be time-
consuming.10,15,26 In contrast to Gallagher et al, this study 
observed the time to deliver this type of medication review 
and resulting PI(s) in an acute hospital in Ireland. The 
advantages of this approach is that it was not subject to 
bias, increased accuracy and provided real-world data.
Various approaches to eliciting probability distributions 
have been completed.27 All are grounded in the SHeffield 
ELicitation Framework (SHELF).28 There are five 
elicitation methods available online using the web-based 
MATCH Uncertainty Elicitation Tool.27 Of the five 
elicitation techniques, the probability method was the most 
similar to this study.27 Due to a lack of time and resources, 
these eliciting methods were not applied. However, for 
future research, the MATCH Uncertainty Elicitation Tool 
would be helpful to determine agreement between raters.
Conclusion
The projected annual net benefit is between €29.5–€31.2 m 
over this 5-year period based on the model assumptions 
outlined. The implementation of this type of clinical 
pharmacy service is likely to have a positive effect on 
health outcomes and reduce direct costs to the healthcare 
system. If this service was provided more widely in all 
Irish hospitals, there is scope to achieve further benefits.
The results of this study confirmed previous work and 
supplemented the body of evidence that medication 
reviews play a key role in preventing potential ADEs while 
generating savings.
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Figure 2. Cost benefit ratios.
Due to the assumption of bi-weekly medication reviews length of stay was not reflected on this table.
Table 3. Demographics of study patients.
Demographic Description Patients with PI(s)
n = 213
Patients with no PI(s)
n = 1003
Gender (n) Male 80 (37.6%) 458 (45.7%)
Female 133 (62.4%) 545 (54.3%)
Speciality (n) Medicine 191 (89.7%) 820 (78.2%)
Surgery 22 (10.3%) 229 (21.8%)
Age (years) Median 74 65
IQR 15 25
⩾65 years n = 164 (77.0%) n = 521 (51.9%)




PI(s): pharmacist intervention(s); n: number of patients; IQR: interquartile range.
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Table 5. Projected Cost and savings from ADEs avoided for Daily Medication reviews.
2017 2018 2019 2020 2021
Estimated populationa 4,796,537 4,859,137 4,922,555 4,986,800 5,051,884
Total inpatient dischargesb 643,008 651,932 660,980 670,153 679,454
Total cost of service* €20,081,138 €20,359,837 €20,642,404 €20,928,893 €21,219,358
Expected monetary benefit 
from ADE avoided
€118,017,676 €119,655,603 €121,316,263 €122,999,970 €124,707,045
Projected net benefit €97,936,537 €99,295,766 €100,673,858 €102,071,076 €103,487,686
Projected net benefit** €96,174,696 €97,509,472 €98,862,773 €100,234,856 €101,625,982
Projected net benefit*** €107,234,433 €108,722,703 €110,231,629 €111,761,496 €113,312,596
ADE: adverse drug event.
Projections do not take into account changes in activity due to models of care, disease patterns, medical inflation, changes in policy on eligibility, the 
health of the population, the expectations of the public or the state of the national economy.
aProjected population estimates Census 2016 M1F1 scenario (CSO, 2016).
bProjected inpatient discharges HIPE (2015).
*Assuming all patients receive a daily medication review, **6.52 days, ***7.27 days.
Table 4. Types and prevalence of PIs (n = 313) in 213 patients.
Type of PI No. of PIs (%)
Duplication 87 (27.8)
 Co-prescribe same drug class 45 (14.4)
 Co-prescribe same drug 42 (13.4)
Poor prescribing practice 41 (13.1)
 Frequency of administration unclear 24 (7.7)
 Dose charted unclear 13 (4.1)
 Drug charted unclear 4 (1.3)
Frequencya 38 (12.1)
 More than licenced frequency 21 (6.7)
 Less than licenced frequency 17 (5.4)
Dosea 33 (10.6)
 More than licenced dose 25 (8.0)
 Less than licenced dose 8 (2.6)
Drug–drug interactiona 32 (10.2)
 Pharmacokinetic 30 (9.6)
 Pharmacodynamic 2 (0.6)
Timinga,b 27 (8.6)







aAs per summary of product characteristics.
bAs per British National Formulary 71[15].
cRelative to admission notes, this intervention was opportunistic.
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Table 6. Projected cost for medication reviews.
2017 2018 2019 2020 2021
Estimated populationa 4,796,537 4,859,137 4,922,555 4,986,800 5,051,884
Total inpatient dischargesb 643,008 651,932 660,980 670,153 679,454
Total cost of service** €8,256,222 €8,370,807 €8,486,983 €8,604,771 €8,724,193
Expected increase in cost 
of service**
€2,211,947 €2,242,646 €2,273,771 €2,305,328 €2,337,323
Expected monetary benefit 
from ADE avoided
€35,545,478 €36,038,802 €36,538,972 €37,046,084 €37,560,235
Projected net benefit €27,289,256 €27,667,994 €28,051,989 €28,441,313 €28,836,041
Projected net benefit* €31,365,927 €31,801,244 €32,242,603 €32,690,087 €33,143,781
Projected net benefit** €26,903,452 €27,276,836 €27,655,402 €28,039,222 €28,428,369
ADE: adverse drug event.
Projections do not take into account changes in activity due to models of care, disease patterns, medical inflation, changes in policy on eligibility, the 
health of the population, the expectations of the public or the state of the national economy.
aProjected population estimates Census 2016 M1F1 scenario (CSO, 2016).
bProjected inpatient discharges HIPE (2015).
*Lowest point on salary scale for pharmacist.
**Highest point on salary scale for senior pharmacist.
